- Main
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
- Shalapour, Shabnam;
- Lin, Xue-Jia;
- Bastian, Ingmar N;
- Brain, John;
- Burt, Alastair D;
- Aksenov, Alexander A;
- Vrbanac, Alison F;
- Li, Weihua;
- Perkins, Andres;
- Matsutani, Takaji;
- Zhong, Zhenyu;
- Dhar, Debanjan;
- Navas-Molina, Jose A;
- Xu, Jun;
- Loomba, Rohit;
- Downes, Michael;
- Yu, Ruth T;
- Evans, Ronald M;
- Dorrestein, Pieter C;
- Knight, Rob;
- Benner, Christopher;
- Anstee, Quentin M;
- Karin, Michael
- et al.
Published Web Location
https://doi.org/10.1038/nature24302Abstract
The role of adaptive immunity in early cancer development is controversial. Here we show that chronic inflammation and fibrosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accumulation of liver-resident immunoglobulin-A-producing (IgA+) cells. These cells also express programmed death ligand 1 (PD-L1) and interleukin-10, and directly suppress liver cytotoxic CD8+ T lymphocytes, which prevent emergence of hepatocellular carcinoma and express a limited repertoire of T-cell receptors against tumour-associated antigens. Whereas CD8+ T-cell ablation accelerates hepatocellular carcinoma, genetic or pharmacological interference with IgA+ cell generation attenuates liver carcinogenesis and induces cytotoxic T-lymphocyte-mediated regression of established hepatocellular carcinoma. These findings establish the importance of inflammation-induced suppression of cytotoxic CD8+ T-lymphocyte activation as a tumour-promoting mechanism.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-